Skip to main content

Table 4 FDA-approved combination regimens of immunotherapy and targeted therapies

From: Combination strategies to maximize the benefits of cancer immunotherapy

Cancer

Line of therapy

Targeted therapy

Immunotherapy

Clinical benefit

Statistics

Trial name and reference

Kidney cancer

Metastatic, 1st line

Axitinib

Pembrolizumab

12-Mo OS: 89.9% versus 78.3%

HR 0.53; 95% CI 0.38 to 0.74; P < 0.0001

KEYNOTE-426, [301]

Kidney cancer

Metastatic, 1st line

Cabozantinib

Nivolumab

PFS 16.6 versus 8.3

HR 0.51; 95% CI 0.41 to 0.64; P < 0.001

CheckMate -9ER, [303]

Kidney cancer

Metastatic, 1st line

Axitinib

Avelumab

PFS 13.8 versus 7.2 mos,

HR 0.61; 95% CI, 0.47 to 0.79; P < 0.001

JAVELIN Renal 101, [302]

Endometrial cancer not MSI-H or dMMR

Metastatic, salvage

Lenvatinib

Pembrolizumab

ORR of 38.3% (95% CI, 29–49%)

Single-arm trial

KEYNOTE-146, [306]

Hepatocellular carcinoma

Unresectable, 1st line

Bevacizumab

Atezolizumab

12-mo OS: 67.2% versus 54.6% for sorafenib

HR 0.58; 95% CI 0.42 to 0.79; P < 0.001

IMbrave150, [309]

BRAF V600( +) advanced melanoma

Advanced, 1st line

Vemurafenib + cobimetinib

Atezolizumab

PFS 15.1 versus 10.6 mo

HR 0·78; 95% CI 0·63–0·97; p = 0·025

IMspire150, [313]